NO20080052L - G-Protein kopplede reseptoragonister - Google Patents
G-Protein kopplede reseptoragonisterInfo
- Publication number
- NO20080052L NO20080052L NO20080052A NO20080052A NO20080052L NO 20080052 L NO20080052 L NO 20080052L NO 20080052 A NO20080052 A NO 20080052A NO 20080052 A NO20080052 A NO 20080052A NO 20080052 L NO20080052 L NO 20080052L
- Authority
- NO
- Norway
- Prior art keywords
- receptor agonists
- coupled receptor
- protein coupled
- obesity
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0513276A GB0513276D0 (en) | 2005-06-30 | 2005-06-30 | Compounds |
GB0612897A GB0612897D0 (en) | 2006-06-29 | 2006-06-29 | GPCR agonists |
PCT/GB2006/050182 WO2007003964A1 (en) | 2005-06-30 | 2006-06-30 | G-protein coupled receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20080052L true NO20080052L (no) | 2008-01-23 |
Family
ID=37057179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20080052A NO20080052L (no) | 2005-06-30 | 2008-01-04 | G-Protein kopplede reseptoragonister |
Country Status (11)
Country | Link |
---|---|
US (1) | US20090203676A1 (ja) |
EP (1) | EP1909791A1 (ja) |
JP (1) | JP2008545010A (ja) |
KR (1) | KR20080025190A (ja) |
AU (1) | AU2006264651A1 (ja) |
BR (1) | BRPI0612599A2 (ja) |
CA (1) | CA2613236A1 (ja) |
MX (1) | MX2007016545A (ja) |
NO (1) | NO20080052L (ja) |
NZ (1) | NZ564758A (ja) |
WO (1) | WO2007003964A1 (ja) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004065380A1 (en) | 2003-01-14 | 2004-08-05 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
US20070197590A1 (en) * | 2006-01-31 | 2007-08-23 | Demong Duane E | Substituted dipiperidine ccr2 antagonists |
US20090221639A1 (en) * | 2006-04-06 | 2009-09-03 | Lisa Sarah Bertram | Heterocyclic GPCR Agonists |
DK1971862T3 (da) | 2006-04-11 | 2011-02-14 | Arena Pharm Inc | Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
EP2121661A1 (en) * | 2006-12-20 | 2009-11-25 | Merck & Co., Inc. | Bipiperidinyl compounds, compositions containing such compounds and methods of treatment |
CA2674360A1 (en) * | 2007-01-04 | 2008-07-10 | Prosidion Limited | Piperidine gpcr agonists |
CL2008000018A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
PE20081849A1 (es) | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
US20100048632A1 (en) | 2007-01-04 | 2010-02-25 | Matthew Colin Thor Fyfe | Piperidine GPCR Agonists |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP2200609A1 (en) | 2007-09-10 | 2010-06-30 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
NZ583495A (en) * | 2007-09-20 | 2011-11-25 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
JP2011506295A (ja) | 2007-12-05 | 2011-03-03 | アストラゼネカ アクチボラグ | ピペラジン誘導体およびそのレプチン受容体モジュレータとしての使用 |
JP2011513232A (ja) * | 2008-02-22 | 2011-04-28 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Gpr119活性のモジュレーターとしての化合物および組成物 |
EA201001330A1 (ru) * | 2008-02-22 | 2011-04-29 | Айрм Ллк | Соединения и композиции в качестве модуляторов активности gpr119 |
EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
WO2009129036A1 (en) | 2008-04-14 | 2009-10-22 | Merck & Co., Inc. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
EP2379542B1 (en) | 2008-12-24 | 2013-02-13 | Cadila Healthcare Limited | Novel oxime derivatives |
GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB0904284D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
JP2012530758A (ja) | 2009-06-24 | 2012-12-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物、医薬組成物及びそれに関する方法 |
EA201200046A1 (ru) | 2009-06-24 | 2012-08-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Новые соединения, фармацевтическая композиция и связанные с ними способы |
WO2011002067A1 (ja) * | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
BR112012003973A2 (pt) | 2009-08-26 | 2015-09-08 | Sanofi Sa | hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso |
MX2012004078A (es) * | 2009-10-09 | 2012-07-25 | Irm Llc | Compuestos y composiciones como moduladores de la actividad de gpr119. |
CN108558740B (zh) | 2010-01-27 | 2021-10-19 | 艾尼纳制药公司 | S1p1受体调节剂及其盐的制备方法 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるgpr119作動薬とddp−iv阻害薬リナグリプチンの組合せ |
GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
CN103080101A (zh) | 2010-05-17 | 2013-05-01 | 阵列生物制药公司 | 作为gpr119调节剂的哌啶基取代的内酰胺 |
TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
PE20131371A1 (es) | 2010-09-22 | 2013-11-25 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este |
AP2013006812A0 (en) | 2010-10-08 | 2013-04-30 | Cadila Healthcare Ltd | Novel GRP 119 agonists |
GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
WO2012066077A1 (en) | 2010-11-18 | 2012-05-24 | Prosidion Limited | 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2693882B1 (en) | 2011-04-08 | 2017-06-28 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
WO2012145361A1 (en) * | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) * | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
ES2602813T3 (es) | 2011-06-09 | 2017-02-22 | Rhizen Pharmaceuticals S.A. | Nuevos compuestos como moduladores de GPR-119 |
EP2720544B1 (en) | 2011-06-16 | 2016-12-21 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013048916A1 (en) | 2011-09-30 | 2013-04-04 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
WO2013062838A1 (en) | 2011-10-24 | 2013-05-02 | Merck Sharp & Dohme Corp. | Substituted piperidinyl compounds useful as gpr119 agonists |
WO2013062837A1 (en) * | 2011-10-24 | 2013-05-02 | Merck Sharp & Dohme Corp. | Piperidine derivatives useful as gpr119 agonists |
US20140256756A1 (en) * | 2011-11-03 | 2014-09-11 | Array Biopharma Inc. | Piperidinyl-substituted lactams as gpr119 modulators |
US9018224B2 (en) | 2011-11-15 | 2015-04-28 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as GPR119 agonists |
JP6163205B2 (ja) | 2012-06-20 | 2017-07-12 | ノバルティス アーゲー | 補体経路モジュレーターおよびその使用 |
EP3200589A4 (en) | 2014-09-10 | 2018-07-25 | Temple University Of The Commonwealth System Of Higher Education | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
KR20230151072A (ko) | 2015-01-06 | 2023-10-31 | 아레나 파마슈티칼스, 인크. | S1p1 수용체와 관련된 상태의 치료 방법 |
CA3002551A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders |
EP3337788A4 (en) | 2015-08-21 | 2019-03-27 | Portola Pharmaceuticals, Inc. | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN / -KEXIN TYPE 9 P (CSK9) MODULATORS AND THEIR USE |
US10821106B2 (en) | 2015-08-21 | 2020-11-03 | Srx Cardio, Llc | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity |
US10865185B2 (en) | 2015-08-21 | 2020-12-15 | Srx Cardio, Llc | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity |
WO2017147328A1 (en) | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
WO2024072930A1 (en) * | 2022-09-30 | 2024-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3332949A (en) * | 1962-11-13 | 1967-07-25 | Sterling Drug Inc | 1-phenyl-4-[2-(2-pyridyl)-ethyl] piperazines |
US3133061A (en) * | 1962-11-13 | 1964-05-12 | Sterling Drug Inc | Piperidine carboxamides and derivatives thereof |
FR2285883A1 (fr) * | 1974-09-30 | 1976-04-23 | Cerm Cent Europ Rech Mauvernay | Nouveaux composes chimiques a activite bronchospasmolytique et antitussive, et procede pour leur obtention |
US5229398A (en) * | 1990-02-27 | 1993-07-20 | Adir Et Compagnie | Aminomethylpiperidine compounds |
GB9516709D0 (en) * | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
DE19614204A1 (de) * | 1996-04-10 | 1997-10-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6093718A (en) * | 1996-08-14 | 2000-07-25 | Zeneca Limited | Substituted pyrimidine derivatives and their pharmaceutical use |
US6391880B1 (en) * | 1997-02-13 | 2002-05-21 | Zeneca Limited | Heterocyclic compounds useful as oxido-squalene cyclase inhibitors |
WO1998035956A1 (en) * | 1997-02-13 | 1998-08-20 | Zeneca Limited | Heterocyclic compounds useful as oxido-squalene cyclase inhibitors |
EP1003512A1 (en) * | 1997-06-18 | 2000-05-31 | Merck & Co., Inc. | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS |
US6255302B1 (en) * | 1998-12-17 | 2001-07-03 | American Home Products Corporation | 1,4-piperazine derivatives |
EP1301484A2 (en) * | 2000-07-20 | 2003-04-16 | Neurogen Corporation | Capsaicin receptor ligands |
US6667319B2 (en) * | 2001-07-26 | 2003-12-23 | Schering-Plough Corporation | Neuropeptide Y Y5 receptor antagonists |
ES2197003B1 (es) * | 2002-04-08 | 2005-03-16 | J. URIACH & CIA S.A. | Nuevos compuestos antagonistas de integrinas alfa. |
AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
AR047759A1 (es) * | 2003-09-26 | 2006-02-22 | Vertex Pharma | Derivados de fenil - piperazina como moduladores de receptores muscarnicos |
EP1838311A1 (en) * | 2004-12-24 | 2007-10-03 | Prosidion Limited | G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes |
MX2007010076A (es) * | 2005-02-17 | 2007-10-16 | Astellas Pharma Inc | Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo. |
-
2006
- 2006-06-30 MX MX2007016545A patent/MX2007016545A/es unknown
- 2006-06-30 CA CA002613236A patent/CA2613236A1/en not_active Abandoned
- 2006-06-30 EP EP06744362A patent/EP1909791A1/en not_active Withdrawn
- 2006-06-30 JP JP2008520009A patent/JP2008545010A/ja active Pending
- 2006-06-30 KR KR1020087002531A patent/KR20080025190A/ko not_active Application Discontinuation
- 2006-06-30 BR BRPI0612599-9A patent/BRPI0612599A2/pt not_active IP Right Cessation
- 2006-06-30 AU AU2006264651A patent/AU2006264651A1/en not_active Abandoned
- 2006-06-30 NZ NZ564758A patent/NZ564758A/en not_active IP Right Cessation
- 2006-06-30 WO PCT/GB2006/050182 patent/WO2007003964A1/en active Application Filing
- 2006-06-30 US US11/922,826 patent/US20090203676A1/en not_active Abandoned
-
2008
- 2008-01-04 NO NO20080052A patent/NO20080052L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20090203676A1 (en) | 2009-08-13 |
EP1909791A1 (en) | 2008-04-16 |
JP2008545010A (ja) | 2008-12-11 |
BRPI0612599A2 (pt) | 2010-11-23 |
WO2007003964A1 (en) | 2007-01-11 |
CA2613236A1 (en) | 2007-01-11 |
AU2006264651A1 (en) | 2007-01-11 |
MX2007016545A (es) | 2008-02-21 |
NZ564758A (en) | 2011-03-31 |
KR20080025190A (ko) | 2008-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20080052L (no) | G-Protein kopplede reseptoragonister | |
NO20080010L (no) | GPCR-agonister | |
EA015805B9 (ru) | Пиперидиновые агонисты gpcr | |
NO20084364L (no) | Azetidin derivater som G-protein koblet reseptor (GPR119) agonister | |
NO20084307L (no) | Heterocykliske GPCR agonister | |
CY1112483T1 (el) | Αγωνιστες gpcr πιπεριδινης | |
EA200900880A1 (ru) | Пиперидиновые агонисты gpcr | |
WO2007003961A3 (en) | Gpcr agonists | |
HK1158192A1 (en) | Piperidine gpcr agonists | |
ATE557023T1 (de) | Piperidinylverbindungen als gpcr-agonisten | |
BRPI0418149A (pt) | derivados heterocìclicos como agonistas do receptor de gprc | |
NO20065260L (no) | Tri(cyklo)substituerte amidforbindelser | |
NO20082445L (no) | Neuropeptid-2 reseptor-agonister | |
CL2008003847A1 (es) | Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad. | |
MX2009011358A (es) | Derivados de pirimidinona y metodos para su uso. | |
WO2010036613A8 (en) | Novel cyclic benzimidazole derivatives useful anti-diabetic agents | |
ATE516300T1 (de) | Neuromedin-u-rezeptoragonisten und ihre verwendung | |
BRPI0516407A (pt) | agonistas de receptor acoplado à proteìna g (gpr116) e uso destes para o tratamento de obesidade e diabetes | |
NO20091734L (no) | Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse | |
MX2008002062A (es) | Uso de derivados de tienopiridona como activadores de ampk y composiciones farmaceuticas que los contienen. | |
NO20053742L (no) | Tri (cyclo)-substituerte amidforbindelser | |
NO20084403L (no) | Cykloheksylpyrazol-lactamderivater som inhibitorer av II-beta-hydroksysteroid dehydrogenase I | |
CY1110753T1 (el) | Αναστολεις της 11-βητα-υδροξυστεροειδους αφυδρογονασης i | |
NO20074441L (no) | 1-benzylindol-2-karboksamidderivater | |
DE602004012858D1 (de) | 2-aminobenzothiazole als cb1 rezeptor inverse agonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |